Author

N. P. Restifo

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Immunology· 2 Cell Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cell type annotation· 4 Research Focus:drug response / drug discovery· 4 Organism:human· 4 Research Focus:differential expression· 3 Approach:experimental assay· 3 Research Focus:gene regulatory network inference· 3 Assay:bulk RNA-seq· 2 Approach:genetic perturbation / CRISPR· 2

Frequent Co-Authors

S. K. Vodnala· 4 shared R. J. Kishton· 3 shared D. C. Deniger· 2 shared D. C. Palmer· 2 shared D. Gurusamy· 2 shared P. Malekzadeh· 2 shared S. J. Patel· 2 shared W. Lo· 2 shared

Activity by Year

2019-2021 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 37 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersImmunology

S. K. Vodnala

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

Self-organized yolk sac-like organoids allow for scalable generation of multipotent hematopoietic progenitor cells from human induced pluripotent stem cells

N. Tamaoki, S. Siebert, T. Maeda, N.-H. Ha, M. L. Good, Y. Huang, S. K. Vodnala, J. J. H. Mora, U. Naoya, J. F. Tisdale, C. L. Sweeney, U. Choi, J. Brault, S. Koontz, H. L. Malech, , R. Vizcardo

This study develops yolk sac-like organoids from hiPSCs to generate multipotent hematopoietic progenitor cells in a scalable and xeno-free system.

bioRxiv · Apr 25, 2021Cell Biology

Internal checkpoint regulates T cell neoantigen reactivity and susceptibility to PD1 blockade

D. C. Palmer, B. R. Webber, Y. Patel, M. J. Johnson, C. M. Kariya, W. S. Lahr, M. R. Parkhurst, J. J. Gartner, T. D. Prickett, F. J. Lowery, R. J. Kishton, D. Gurusamy, Z. Franco, S. K. Vodnala, M. D. Diers, , N. P. Restifo

This study shows that CISH knockout in TIL enhances neoantigen reactivity and synergizes with PD1 blockade to improve tumor regression.

bioRxiv · Sep 24, 2020Immunology

Genome-wide Screens Identify Lineage- and Tumor Specific-Genes Modulating MHC-I and MHC-II Immunosurveillance in Human Lymphomas

D. Dersh, J. D. Phelan, M. E. Gumina, B. Wang, J. H. Arbuckle, J. Holly, R. J. Kishton, T. E. Markowitz, M. O. Seedhom, N. Fridlyand, G. W. Wright, D. W. Huang, M. Ceribelli, C. J. Thomas, J. B. Lack, , J. W. Yewdell

The paper identifies genes modulating MHC-I and MHC-II expression in lymphomas, revealing potential targets for immunosurveillance manipulation.

bioRxiv · Mar 13, 2020Cancer Biology

Genome-wide profiling of druggable active tumor defense mechanisms to enhance cancer immunotherapy

R. J. Kishton, S. J. Patel, S. K. Vodnala, A. K. Decker, Y. Patel, M. Sukumar, T. N. Yamamoto, Z. Yu, M. Ji, A. N. Henning, D. Gurusamy, D. C. Palmer, W. Lo, A. Pasetto, P. Malekzadeh, , N. P. Restifo

This study identifies genes that tumor cells use to resist T cell killing and shows that inhibiting BIRC2, ITGAV, or DNPEP enhances T cell-mediated tumor destruction.

bioRxiv · Nov 18, 2019 · PreprintImmunology

Multi-model preclinical platform predicts clinical response of melanoma to immunotherapy

E. Perez-Guijarro, H. H. Yang, R. E. Araya, R. El Meskini, H. T. Michael, S. K. Vodnala, K. L. Marie, C. Graff-Cherry, S. Chin, A. J. Iacovelli, A. Kulaga, A. Fon, A. M. Michalowski, W. Hugo, R. S. Lo, , G. Merlino

The paper develops a preclinical platform using syngeneic mouse models to predict melanoma patient response to immunotherapy and identifies a melanocytic plasticity signature linked to treatment outcomes.

bioRxiv · Aug 6, 2019 · PreprintCancer Biology